Inquiry Basket
C-lock-PEG4-MMAE is a thiol-reactive drug-linker conjugate used in the synthesis of antibody-drug conjugates (ADCs).
| Catalog Number | Size | Price | Quantity | ||
|---|---|---|---|---|---|
| BADC-01416 | -- | $-- | Inquiry |
C-lock-PEG4-MMAE, a groundbreaking conjugate of the potent cytotoxic agent monomethyl auristatin E (MMAE) fused through a polyethylene glycol (PEG) spacer, opens up a realm of diverse opportunities in bioscience. Below are four applications:
Antibody-Drug Conjugates (ADCs) Development: Spearheading the frontier of targeted cancer therapy, C-lock-PEG4-MMAE plays a pivotal role in shaping the landscape of ADCs. By intricately linking this potent compound with tailored antibodies designed for cancer cells, the cytotoxic MMAE can be selectively guided to the tumor microenvironment. This precision targeting strategy not only mitigates harm to healthy tissues but also amplifies the therapeutic impact of anti-cancer treatments.
Tumor Profiling and Imaging: In the intricate realm of tumor biology, C-lock-PEG4-MMAE emerges as a valuable tool for illuminating tumor imaging studies. By harnessing this innovative conjugate, researchers can delve into the distribution and uptake dynamics of ADCs within cancerous tissues. This detailed tumor profiling aids in assessing the efficacy and efficiency of ADC binding, setting the stage for refined dosing strategies and improved treatment outcomes.
Pharmacokinetic and Toxicity Studies: With the unique attributes conferred by PEG4, C-lock-PEG4-MMAE stands out as an optimal candidate for unraveling pharmacokinetic mysteries. Researchers can leverage this compound to untangle the complexities of ADC distribution, metabolism, and clearance in preclinical models. This comprehensive evaluation sheds light on the safety profile and potential toxicities of therapeutic interventions, guiding the development of safer and more efficacious treatments.
Preclinical Drug Screening: Leading the charge in preclinical drug discovery endeavors, C-lock-PEG4-MMAE serves as a cornerstone for assessing the efficacy of novel antibody targets. By merging this model compound with a diverse array of antibodies, scientists can swiftly gauge the therapeutic potential of various ADC candidates. This streamlined screening process hastens drug discovery timelines and facilitates the identification of promising candidates poised for clinical translation.
Customer Support
Providing excellent 24/7 customer service and support
Project Management
Offering 100% high-quality services at all stages
Quality Assurance
Ensuring the quality and reliability of products or services
Global Delivery
Ensuring timely delivery of products worldwide
BOC Sciences offers comprehensive services for ADC manufacturing, including antibody modification, linker chemistry, payload conjugation, and formulation development. In particular, our payload-linker customization service offers a convenient and fast raw material channel for many ADC researchers.
BOC Sciences provides one-stop site-specific conjugation services for amino acids, glycans, unnatural amino acids, and short peptide tags. In addition, cysteine conjugation, lysine conjugation, enzymatic conjugation, thio-engineered antibody can also be obtained quickly.
BOC Sciences offers a full range of linkers, including peptide linkers, PEG linkers, click chemistry, PROTAC linkers, non-cleavable linkers, etc. We also provide custom development services for chemically labile linkers and enzymatically cleavable linkers.
